More recently, a retrospective study of patient samples with non-metastatic prostate cancer revealed that all annexin A2-positive tumors (n = 40) relapsed compared to only half in annexin A2-negative tumors. This evidence concerns the gene ANXA2 and Familial prostate cancer.